Results 171 to 180 of about 7,490 (233)

B cell antigen receptor-induced plasma membrane recruitment of the SH2 domain-containing inositol phosphatase is mediated by the protein tyrosine kinases Lyn and Syk [PDF]

core   +1 more source

Pseudoangiosarcoma and cutaneous collagenous vasculopathy in a patient on a Bruton's tyrosine kinase inhibitor. [PDF]

JAAD Case Rep
Kucharik AH, Curkovic NB, Chavez JC, Tsai KY, Brohl AS, Grichnik JM.   +5 more
europepmc   +1 more source

PROTAC for Bruton's tyrosine kinase degradation alleviates inflammation in autoimmune diseases. [PDF]

Cell Discov
Zhu C, Yang Z, Zhang Y, Li Z, Li G, Yang B, Kang N, Wang J, Sun Y, Ding N, Rao Y, Liu W.   +11 more
europepmc   +1 more source

Bruton's tyrosine kinase (Btk) のSH3ドメイン結合蛋白質SabによるBtk活性の制御 [PDF]

ヤマドリ, トモキ, 山鳥, 大材
core  

The Evolving Role of Bruton's Tyrosine Kinase Inhibitors in B Cell Lymphomas. [PDF]

Int J Mol Sci
Mehra S, Nicholls M, Taylor J.
europepmc   +1 more source

Vascular Endothelial Growth Factors and the Bmx Tyrosine Kinase in the Regulation of Angiogenesis and Lymphangiogenesis [PDF]

, 2003
Paavonen, Karri
core  

Retraction: X-linked immunodeficient mice with no functional Bruton's tyrosine kinase are protected from sepsis-induced multiple organ failure. [PDF]

Front Immunol
Frontiers Editorial Office.
europepmc   +1 more source

Evaluation of Bruton's Tyrosine Kinase (BTK) inhibition with alternative doses of ibrutinib in subjects with Chronic Lymphocytic Leukemia (CLL). [PDF]

Cancer Chemother Pharmacol
Ouerdani A, Valenzuela B, Treijtel N, Haddish-Berhane N, Desphande S, Srinivasan S, Smith E, Perez Ruixo JJ.   +7 more
europepmc   +1 more source

Inhibition of head and neck squamous cell carcinoma by Bruton's tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells. [PDF]

Cancer Immunol Immunother
Bopp AR, Lamenza FF, Upadhaya P, Ryan NM, Kazmierowicz N, Jordanides PP, Siddiqui A, Pracha SH, Roth P, Iwenofu OH, Oghumu S.   +10 more
europepmc   +1 more source